These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 9346488)

  • 41. Recombinant human hemoglobins designed for gene therapy of sickle cell disease.
    McCune SL; Reilly MP; Chomo MJ; Asakura T; Townes TM
    Proc Natl Acad Sci U S A; 1994 Oct; 91(21):9852-6. PubMed ID: 7937904
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rearrangements of the beta-globin gene cluster in apparently typical betaS haplotypes.
    Zago MA; Silva WA; Gualandro S; Yokomizu IK; Araujo AG; Tavela MH; Gerard N; Krishnamoorthy R; Elion J
    Haematologica; 2001 Feb; 86(2):142-5. PubMed ID: 11224482
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mutant mice mimic human sickle cell anemia.
    Barinaga M
    Science; 1997 Oct; 278(5339):803-4. PubMed ID: 9381190
    [No Abstract]   [Full Text] [Related]  

  • 44. Systematic enhancement of polymerization of recombinant sickle hemoglobin mutants: implications for transgenic mouse model for sickle cell anemia.
    Li X; Mirza UA; Chait BT; Manning JM
    Blood; 1997 Dec; 90(11):4620-7. PubMed ID: 9373274
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Protective effect of arginine on oxidative stress in transgenic sickle mouse models.
    Dasgupta T; Hebbel RP; Kaul DK
    Free Radic Biol Med; 2006 Dec; 41(12):1771-80. PubMed ID: 17157180
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Arginine supplementation improves rotorod performance in sickle transgenic mice.
    Fasipe FR; Ubawike AE; Eva R; Fabry ME
    Hematology; 2004 Aug; 9(4):301-5. PubMed ID: 15621739
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Fibrinogen deficiency, but not plasminogen deficiency, increases mortality synergistically in combination with sickle hemoglobin SAD in transgenic mice.
    Roszell NJ; Danton MJ; Jiang M; Witte D; Daugherty C; Grimes T; Girdler B; Anderson KP; Franco RS; Degen JL; Joiner CH
    Am J Hematol; 2007 Dec; 82(12):1044-8. PubMed ID: 17722076
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Correction of sickle cell disease by homologous recombination in embryonic stem cells.
    Wu LC; Sun CW; Ryan TM; Pawlik KM; Ren J; Townes TM
    Blood; 2006 Aug; 108(4):1183-8. PubMed ID: 16638928
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sickle cell disease due to compound heterozygosity for Hb S and a novel 7.7-kb beta-globin gene deletion.
    Andersson BA; Wering ME; Luo HY; Basran RK; Steinberg MH; Smith HP; Chui DH
    Eur J Haematol; 2007 Jan; 78(1):82-5. PubMed ID: 17038017
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Structure of fully liganded Hb ζ2β2s trapped in a tense conformation.
    Safo MK; Ko TP; Abdulmalik O; He Z; Wang AH; Schreiter ER; Russell JE
    Acta Crystallogr D Biol Crystallogr; 2013 Oct; 69(Pt 10):2061-71. PubMed ID: 24100324
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Transgenic and gene knock-out mouse models of sickle cell anemia and the thalassemias.
    Pászty C
    Curr Opin Hematol; 1997 Mar; 4(2):88-93. PubMed ID: 9107524
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pathophysiology of sickle cell disease.
    Steinberg MH
    Baillieres Clin Haematol; 1998 Mar; 11(1):163-84. PubMed ID: 10872477
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Use of restriction endonucleases for mapping the allele for beta s-globin.
    Wilson JT; Milner PF; Summer ME; Nallaseth FS; Fadel HE; Reindollar RH; McDonough PG; Wilson LB
    Proc Natl Acad Sci U S A; 1982 Jun; 79(11):3628-31. PubMed ID: 6285354
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Gene replacement therapy for sickle cell disease and other blood disorders.
    Townes TM
    Hematology Am Soc Hematol Educ Program; 2008; ():193-6. PubMed ID: 19074080
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vivo blood flow abnormalities in the transgenic knockout sickle cell mouse.
    Embury SH; Mohandas N; Paszty C; Cooper P; Cheung AT
    J Clin Invest; 1999 Mar; 103(6):915-20. PubMed ID: 10079113
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Loss of NRF2 function exacerbates the pathophysiology of sickle cell disease in a transgenic mouse model.
    Zhu X; Xi C; Thomas B; Pace BS
    Blood; 2018 Feb; 131(5):558-562. PubMed ID: 29255069
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A transgenic mouse model of hemoglobin S Antilles disease.
    Popp RA; Popp DM; Shinpock SG; Yang MY; Mural JG; Aguinaga MP; Kopsombut P; Roa PD; Turner EA; Rubin EM
    Blood; 1997 Jun; 89(11):4204-12. PubMed ID: 9166865
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The transgenic SAD mouse: a model of human sickle cell glomerulopathy.
    De Paepe ME; Trudel M
    Kidney Int; 1994 Nov; 46(5):1337-45. PubMed ID: 7853792
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Concurrent sickle cell anemia and alpha-thalassemia. Effect on pathological properties of sickle erythrocytes.
    Embury SH; Clark MR; Monroy G; Mohandas N
    J Clin Invest; 1984 Jan; 73(1):116-23. PubMed ID: 6690472
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hematologically and genetically distinct forms of sickle cell anemia in Africa. The Senegal type and the Benin type.
    Nagel RL; Fabry ME; Pagnier J; Zohoun I; Wajcman H; Baudin V; Labie D
    N Engl J Med; 1985 Apr; 312(14):880-4. PubMed ID: 2579336
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.